{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:23:13Z","timestamp":1773739393309,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00115-021-01256-0","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T12:02:53Z","timestamp":1642420973000},"page":"191-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spinale Muskelatrophie","Spinal muscular atrophy"],"prefix":"10.1007","volume":"93","author":[{"given":"Pascal","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronka","family":"Horber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joohyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"Kronlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"issue":"1","key":"1256_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","volume":"16","author":"K Vill","year":"2021","unstructured":"Vill\u00a0K et\u00a0al (2021) Newborn screening for spinal muscular atrophy in Germany: clinical results after 2\u00a0years. Orphanet J Rare Dis 16(1):153","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1256_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart\u00a0IEC et al (2017) Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a\u00a0literature review. Orphanet J Rare Dis 12(1):124","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"1256_CR3","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","volume":"75","author":"H Chaytow","year":"2018","unstructured":"Chaytow\u00a0H et\u00a0al (2018) The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci 75(21):3877\u20133894","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1256_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1128\/MCB.06077-11","volume":"32","author":"M Ruggiu","year":"2012","unstructured":"Ruggiu\u00a0M et\u00a0al (2012) A role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy. Mol Cell Biol 32(1):126\u2013138","journal-title":"Mol Cell Biol"},{"key":"1256_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","volume":"109","author":"CJJ Yeo","year":"2020","unstructured":"Yeo\u00a0CJJ, Darras\u00a0BT (2020) Overturning the paradigm of spinal muscular atrophy as Just a\u00a0motor neuron disease. Pediatr Neurol 109:12\u201319","journal-title":"Pediatr Neurol"},{"key":"1256_CR6","volume-title":"GeneReviews","author":"TW Prior","year":"1993","unstructured":"Prior\u00a0TW et\u00a0al (1993) Spinal muscular atrophy. In: Adam\u00a0MP, Ardinger\u00a0HH, Pagon\u00a0RA et\u00a0al (Hrsg) GeneReviews\u00ae. University of Washington, Seattle (WA)"},{"key":"1256_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath\u00a0MC, Prior\u00a0DE, Prior\u00a0TW (2021) Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet 14:11\u201325","journal-title":"Appl Clin Genet"},{"key":"1256_CR8","volume-title":"Variants in gene SMN1","author":"C Miner","year":"2021","unstructured":"Miner\u00a0C (2021) Variants in gene SMN1"},{"issue":"8","key":"1256_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/humu.23555","volume":"39","author":"A Henrie","year":"2018","unstructured":"Henrie\u00a0A et al (2018) ClinVar Miner: demonstrating utility of a\u00a0web-based tool for viewing and filtering ClinVar data. Hum Mutat 39(8):1051\u20131060","journal-title":"Hum Mutat"},{"issue":"6","key":"1256_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00439-002-0828-x","volume":"111","author":"S Ogino","year":"2002","unstructured":"Ogino\u00a0S, Wilson\u00a0RB (2002) Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet 111(6):477\u2013500","journal-title":"Hum Genet"},{"issue":"5875","key":"1256_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea\u00a0GE et\u00a0al (2008) Plastin 3 is a\u00a0protective modifier of autosomal recessive spinal muscular atrophy. Science 320(5875):524\u2013527","journal-title":"Science"},{"issue":"2","key":"1256_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","volume":"100","author":"M Riessland","year":"2017","unstructured":"Riessland\u00a0M et\u00a0al (2017) Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet 100(2):297\u2013315","journal-title":"Am J Hum Genet"},{"issue":"2","key":"1256_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri\u00a0E et\u00a0al (2018) Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28(2):103\u2013115","journal-title":"Neuromuscul Disord"},{"key":"1256_CR14","doi-asserted-by":"crossref","unstructured":"Bodamer\u00a0OA (2021) Spinal muscular atrophy. In: UpToDate, Nordli\u00a0DR, Firth\u00a0HV, Martin\u00a0R (Eds) UpToDate. (https:\/\/www.uptodate.com). Zugegriffen: 14.10.2021","DOI":"10.1097\/01.COT.0000732976.10509.b3"},{"issue":"3","key":"1256_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho\u00a0M et\u00a0al (2018) Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a\u00a0compilation of 2834 reported cases. Neuromuscul Disord 28(3):208\u2013215","journal-title":"Neuromuscul Disord"},{"key":"1256_CR16","unstructured":"Gesellschaft f\u00fcr Neurop\u00e4diatrie e.\u202fV. (GNP) (2021) AWMF-Leitlinie: Spinale Muskelatrophie (SMA), Diagnostik und Therapie. Version 1.1, 16.07.2021. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/022-030l_S1_Spinale-Muskelatropie-SMA-Diagnostik-Therapie_2021-07_1.pdf. Zugegriffen: 14.10.2021."},{"issue":"4","key":"1256_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JND-190428","volume":"6","author":"K Vill","year":"2019","unstructured":"Vill\u00a0K et\u00a0al (2019) One year of newborn screening for SMA\u2014results of a\u00a0German pilot project. J\u00a0Neuromuscul Dis 6(4):503\u2013515","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"1256_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","volume":"57","author":"KJ Swoboda","year":"2005","unstructured":"Swoboda\u00a0KJ et\u00a0al (2005) Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 57(5):704\u2013712","journal-title":"Ann Neurol"},{"issue":"6","key":"1256_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00115-020-00919-8","volume":"91","author":"A Ziegler","year":"2020","unstructured":"Ziegler\u00a0A et al (2020) Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 : consensus paper of the German representatives of the society for pediatric neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German society for muscular diseases (DGM). Nervenarzt 91(6):518\u2013529","journal-title":"Nervenarzt"},{"issue":"18","key":"1256_CR20","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell\u00a0JR et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N\u00a0Engl J Med 377(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"Supplement 15","key":"1256_CR21","first-page":"1828","volume":"94","author":"JW Day","year":"2020","unstructured":"Day\u00a0JW et\u00a0al (2020) Onasemnogene abeparvovec-xioi gene-replacement therapy for spinal muscular atrophy type\u00a01 (SMA1): phase\u00a03 US study (STR1VE) update. Neurology 94(Supplement 15):1828","journal-title":"Neurology"},{"issue":"18","key":"1256_CR22","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel\u00a0RS et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N\u00a0Engl J Med 377(18):1723\u20131732","journal-title":"N Engl J Med"},{"issue":"7","key":"1256_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri\u00a0E et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N\u00a0Engl J Med 378(7):625\u2013635","journal-title":"N Engl J Med"},{"issue":"4","key":"1256_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker\u00a0T et al (2020) Nusinersen in adults with 5q spinal muscular atrophy: a\u00a0non-interventional, multicentre, observational cohort study. Lancet Neurol 19(4):317\u2013325","journal-title":"Lancet Neurol"},{"issue":"1","key":"1256_CR25","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","volume":"8","author":"M Sivaramakrishnan","year":"2017","unstructured":"Sivaramakrishnan\u00a0M et al (2017) Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat Commun 8(1):1476","journal-title":"Nat Commun"},{"issue":"6","key":"1256_CR26","doi-asserted-by":"publisher","first-page":"e00447","DOI":"10.1002\/prp2.447","volume":"6","author":"A Poirier","year":"2018","unstructured":"Poirier\u00a0A et\u00a0al (2018) Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect 6(6):e447","journal-title":"Pharmacol Res Perspect"},{"key":"1256_CR27","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.nmd.2020.08.270","volume":"30","author":"L Servais","year":"2020","unstructured":"Servais\u00a0L et al (2020) FIREFISH Parts 1 and 2: 12-month pooled safety and efficacy outcomes of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA). Neuromuscul Disord 30:S126","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"1256_CR28","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello\u00a0G et\u00a0al (2021) Risdiplam in type 1 spinal muscular atrophy. N\u00a0Engl J Med 384(10):915\u2013923","journal-title":"N Engl J Med"},{"issue":"Supplement 15","key":"1256_CR29","first-page":"1260","volume":"Neurology","author":"E Mercuri","year":"2020","unstructured":"Mercuri\u00a0E et al (2020) SUNFISH Part\u00a02: Efficacy and safety of Risdiplam (RG7916) in patients with type\u00a02 or non-ambulant type\u00a03 spinal muscular atrophy (SMA). Neurology 94(Supplement 15):1260","journal-title":"Part"},{"issue":"Supplement 15","key":"1256_CR30","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1212\/WNL.94.15_supplement.772","volume":"94","author":"C Chiriboga","year":"2020","unstructured":"Chiriboga\u00a0C et al (2020) JEWELFISH: safety and pharmacodynamic data in non-naive patients with spinal muscular atrophy (SMA) receiving treatment with Risdiplam (RG7916). Neurology 94(Supplement 15):772","journal-title":"Neurology"},{"issue":"4","key":"1256_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/mus.27034","volume":"62","author":"Y Harada","year":"2020","unstructured":"Harada\u00a0Y et\u00a0al (2020) Combination molecular therapies for type\u00a01 spinal muscular atrophy. Muscle Nerve 62(4):550\u2013554","journal-title":"Muscle Nerve"},{"issue":"11","key":"1256_CR32","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo\u00a0DC et\u00a0al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord 29(11):842\u2013856","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"1256_CR33","doi-asserted-by":"publisher","first-page":"e019932","DOI":"10.1136\/bmjopen-2017-019932","volume":"8","author":"M Stam","year":"2018","unstructured":"Stam\u00a0M et al (2018) Protocol for a\u00a0phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2\u20134 (SPACE trial). BMJ Open 8(7):e19932","journal-title":"BMJ Open"},{"key":"1256_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pediatrneurol.2017.04.013","volume":"73","author":"S Khirani","year":"2017","unstructured":"Khirani\u00a0S et\u00a0al (2017) Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy. Pediatr Neurol 73:78\u201387e1","journal-title":"Pediatr Neurol"},{"issue":"2","key":"1256_CR35","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s13311-020-01004-3","volume":"18","author":"SA Rudnicki","year":"2021","unstructured":"Rudnicki\u00a0SA et al (2021) Reldesemtiv in patients with spinal muscular atrophy: a\u00a0phase 2 hypothesis-generating study. Neurotherapeutics 18(2):1127\u20131136","journal-title":"Neurotherapeutics"},{"key":"1256_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2862916","author":"D Stoimenis","year":"2019","unstructured":"Stoimenis\u00a0D et\u00a0al (2019) Euglycemic Ketoacidosis in spinal muscular atrophy. Case Rep Pediatr. https:\/\/doi.org\/10.1155\/2019\/2862916","journal-title":"Case Rep Pediatr"},{"issue":"1","key":"1256_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","volume":"14","author":"A Pechmann","year":"2019","unstructured":"Pechmann\u00a0A et al (2019) SMArtCARE\u2014A platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis 14(1):18","journal-title":"Orphanet J Rare Dis"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-021-01256-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T13:10:44Z","timestamp":1726492244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-021-01256-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1256"],"URL":"https:\/\/doi.org\/10.1007\/s00115-021-01256-0","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"16 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>P.\u00a0Martin:<\/b>\u00a0A.\u00a0Finanzielle Interessen: P.\u00a0Martin gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt, Klinik f\u00fcr Neurologie mit Schwerpunkt Epileptologie, Universit\u00e4tsklinikum T\u00fcbingen.<b>V.\u00a0Horber:<\/b>\u00a0A.\u00a0Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Avexis\/Novartis, Biogen.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Fach\u00e4rztin f\u00fcr Kinder- und Jugendmedizin, Neurop\u00e4diaterin, Klinik f\u00fcr Kinder- und Jugendmedizin, Universit\u00e4tsklinikum T\u00fcbingen.<b>J.\u00a0Park:<\/b>\u00a0A.\u00a0Finanzielle Interessen: J.\u00a0Park gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenz\u00e4rztin, \u00c4rztin in Weiterbildung, Institut f\u00fcr Medizinische Genetik und Angewandte Genomik, Universit\u00e4tsklinikum T\u00fcbingen.<b>C.\u00a0Kronlage:<\/b>\u00a0A.\u00a0Finanzielle Interessen: C.\u00a0Kronlage gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt, Klinik f\u00fcr Neurologie mit Schwerpunkt Epileptologie, Universit\u00e4tsklinikum T\u00fcbingen.<b>A.\u00a0Grimm:<\/b>\u00a0A.\u00a0Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Grifols, CSL Behring, Alnylam, Pfizer und Canon.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Stellvertretender \u00e4rztlicher Direktor, Klinik f\u00fcr Neurologie mit Schwerpunkt Epileptologie, Universit\u00e4tsklinikum T\u00fcbingen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}